Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund
7.2.2025 09:14:00 CET | Business Wire | Press release
Appointment of Dr. William Jeffrey to the Board and Bonnie Tomei as CFO
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., to further the development of its optical switches for large scale AI connectivity. Applied Ventures and ICM HPQC Fund are joined by Strategic Investment Fund, Braavos, and continued participation from existing investors Oxford Sciences Enterprises, Cambridge Innovation Capital, and leaders from the global semiconductor industry including Silicon Catalyst and Jalal Bagherli.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207290130/en/
Image by Shabbir Bashar
“What our customers want is a photonic switch to connect their AI clusters that is compatible with existing infrastructure while delivering high bandwidth, low latency and significant power savings. The completion of this round will further our development and help us bring our product to customers to enable not just the savings, but large cluster connectivity,” said Vaysh Kewada, Co-founder and CEO of Salience Labs. “We are also excited to be working closely with our strategic investors who are industry leaders to advance our go-to market schedule.”
“Silicon photonics is a promising technology to deliver significant advancements in energy-efficient performance for AI data centers,” said Anand Kamannavar, Vice President and Global Head of Applied Ventures. “Salience's optical switch solution has the potential to enable a new generation of interconnect network architectures for faster and more efficient AI systems.”
“Salience Labs has done a tremendous job in developing a portfolio of innovative silicon photonics products that addresses critical needs in data center and AI infrastructure market,” said Dr. Jalal Bagherli, investor of Salience Labs and former CEO of Dialog Semiconductor that was acquired by Renesas. “Their customer focused approach in addition to the technology that are based on over a decade of research makes Salience Labs a clear leader to win in this enormous market.”
“Salience Lab’s optical switches will enable unprecedented bandwidth and scalability for the next generation of AI and high-performance data centers. By leveraging light, they will unlock the full capability of modern servers while decreasing power consumption and cost. ICM HPQC is excited to work with Vaysh and the Salience team as lead of the Series A raise,” said Dr. William Jeffrey, Chairman of the technical advisory committee on the ICM HPQC Fund and newly appointed Board Member of Salience Labs.
Appointment of Dr. William Jeffrey as new Board Member
In conjunction with the closing of the Series A financing, Salience Labs is appointing Dr. Jeffrey to the Board of Directors, where he joins Jack Edmondson, Chief Investment Officer of Oxford Sciences Enterprises, and Daniel Armbrust, co-founder of Silicon Catalyst, CEO of the SEMATECH semiconductor consortium and appointee to the Industrial Advisory Committee, which advises the Department of Commerce on the R&D strategy for the CHIPS Act.
Dr. Jeffrey is an astronomer with a career spanning the Executive Office of the President of the United States, to leading HRL (known for its groundbreaking innovations such as the invention of the laser, integrated circuits and liquid crystal displays), to being the Director of the National Institute of Standards and Technology, an institution boasting three Nobel prize laureates and ties to a dozen more, and he served as the CEO of SRI International. Dr. Jeffrey earned a Bachelor of Science in physics from the Massachusetts Institute of Technology and a Ph.D. in astronomy from Harvard University.
Appointment of Bonnie Tomei as Chief Financial Officer
Salience Labs is also announcing its appointment of Bonnie Tomei, a certified public accountant and an industry veteran located in Silicon Valley, California, as Chief Financial Officer.
“With over 20 years of experience including initial public offerings, de-SPAC and a strong business operations background, Ms. Tomei will be a key member of the executive team to realize our strategic and operational objectives, including expanding to the U.S. to serve our key customers,” said Ms. Kewada.
About Salience Labs
Salience Labs Limited is a leader in photonic solutions targeting connectivity for AI datacenter infrastructure. Founded in 2021 and backed by over a decade of research from the University of Oxford in the UK and University of Münster in Germany, Salience’s innovative developments in photonic switching technology enable high-speed, ultra-low latency networking fabrics that remove infrastructure bottlenecks for AI workloads. Learn more at http://www.saliencelabs.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207290130/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom